Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Gains from Investment Securities (2020 - 2023)

Historic Gains from Investment Securities for Caribou Biosciences (CRBU) over the last 4 years, with Q2 2023 value amounting to $170000.0.

  • Caribou Biosciences' Gains from Investment Securities fell 9742.85% to $170000.0 in Q2 2023 from the same period last year, while for Sep 2024 it was $170000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $170000.0 for FY2023, which is 9935.24% down from last year.
  • According to the latest figures from Q2 2023, Caribou Biosciences' Gains from Investment Securities is $170000.0, which was down 9742.85% from $6.6 million recorded in Q2 2022.
  • Caribou Biosciences' Gains from Investment Securities' 5-year high stood at $26.2 million during Q1 2022, with a 5-year trough of $10000.0 in Q4 2020.
  • Its 4-year average for Gains from Investment Securities is $6.1 million, with a median of $1.9 million in 2021.
  • As far as peak fluctuations go, Caribou Biosciences' Gains from Investment Securities skyrocketed by 63714.65% in 2022, and later crashed by 9742.85% in 2023.
  • Quarter analysis of 4 years shows Caribou Biosciences' Gains from Investment Securities stood at $10000.0 in 2020, then soared by 27996.6% to $2.8 million in 2021, then surged by 135.29% to $6.6 million in 2022, then tumbled by 97.43% to $170000.0 in 2023.
  • Its last three reported values are $170000.0 in Q2 2023, $6.6 million for Q2 2022, and $26.2 million during Q1 2022.